Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9458195 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
US8039435 | RHYTHM | Melanocortin receptor ligands |
Oct, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 25, 2027 |
New Chemical Entity Exclusivity (NCE) | Nov 25, 2025 |
New Indication (I) | Jun 16, 2025 |
NCE-1 date: November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic